Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease
Paul M. Lantos, MD, Jeffrey Rumbaugh, MD, Linda K. Bockenstedt, MD, Yngve T. Falck-Ytter, MD, Maria E. Aguero-Rosenfeld, MD, Paul G. Auwaerter, MD, Kelly Baldwin, MD, Raveendhara R. Bannuru, MD, PhD, FAGE, Kiran K. Belani, MD, William R. Bowie, MD, John A. Branda, MD, David B. Clifford, MD, Francis J. DiMario, Jr., MD, John J. Halperin, MD, Peter J. Krause, MD, Valery Lavergne, MD, MSc, FRCPC, Matthew H. Liang, MD, MPH, H. Cody Meissner, MD, Lise E. Nigrovic, MD, MPH, James (Jay) J. Nocton, MD, Mikala C. Osani, Amy A. Pruitt, MD, Jane Rips, Lynda E. Rosenfeld, MD, Margot L. Savoy, MD, MPH, Sunil K. Sood, MD, Allen C. Steere, MD, Franc Strle, MD, PhD, Robert Sundel, MD, Jean Tsao, MS, PhD, Elizaveta E. Vaysbrot, Gary P. Wormser, MD, and Lawrence S. Zemel, MD
Neurology® 2020;00:1-12. doi:10.1212/WNL.0000000000011151
Correspondence Dr. P. M. Lantos
paul.lantos@duke.edu
Summarized below are the 2020 recommendations for the prevention, diagnosis, and treatment of Lyme disease.
The panel followed a systematic process used in the development of other Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) clinical practice guidelines, which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach (figure).
A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text (aan.com/Guidelines/home/GuidelinesDetail/1016).
